Pfizer Basic EPS 2012-2026 | PFE
Pfizer annual/quarterly basic eps history and growth rate from 2012 to 2026. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Pfizer basic eps for the quarter ending March 31, 2026 was $0.47, a 9.62% decline year-over-year.
- Pfizer basic eps for the twelve months ending March 31, 2026 was $1.31, a 5.76% decline year-over-year.
- Pfizer annual basic eps for 2025 was $0.001B, a 3.52% decline from 2024.
- Pfizer annual basic eps for 2024 was $0.001B, a 273.68% increase from 2023.
- Pfizer annual basic eps for 2023 was $0B, a 93.2% decline from 2022.
| Pfizer Annual Basic EPS | |
|---|---|
| 2025 | $1.37 |
| 2024 | $1.42 |
| 2023 | $0.38 |
| 2022 | $5.59 |
| 2021 | $3.92 |
| 2020 | $1.65 |
| 2019 | $2.88 |
| 2018 | $1.90 |
| 2017 | $3.57 |
| 2016 | $1.18 |
| 2015 | $1.13 |
| 2014 | $1.44 |
| 2013 | $3.23 |
| 2012 | $1.96 |
| 2011 | $1.28 |
| Pfizer Quarterly Basic EPS | |
|---|---|
| 2026-03-31 | $0.47 |
| 2025-12-31 | $-0.29 |
| 2025-09-30 | $0.62 |
| 2025-06-30 | $0.51 |
| 2025-03-31 | $0.52 |
| 2024-12-31 | $0.07 |
| 2024-09-30 | $0.79 |
| 2024-06-30 | $0.01 |
| 2024-03-31 | $0.55 |
| 2023-12-31 | $-0.59 |
| 2023-09-30 | $-0.42 |
| 2023-06-30 | $0.41 |
| 2023-03-31 | $0.98 |
| 2022-12-31 | $0.88 |
| 2022-09-30 | $1.54 |
| 2022-06-30 | $1.77 |
| 2022-03-31 | $1.40 |
| 2021-12-31 | $0.61 |
| 2021-09-30 | $1.45 |
| 2021-06-30 | $0.99 |
| 2021-03-31 | $0.87 |
| 2020-12-31 | $0.16 |
| 2020-09-30 | $0.26 |
| 2020-06-30 | $0.63 |
| 2020-03-31 | $0.60 |
| 2019-12-31 | $-0.10 |
| 2019-09-30 | $1.38 |
| 2019-06-30 | $0.91 |
| 2019-03-31 | $0.69 |
| 2018-12-31 | $-0.06 |
| 2018-09-30 | $0.70 |
| 2018-06-30 | $0.66 |
| 2018-03-31 | $0.60 |
| 2017-12-31 | $2.05 |
| 2017-09-30 | $0.48 |
| 2017-06-30 | $0.52 |
| 2017-03-31 | $0.52 |
| 2016-12-31 | $0.13 |
| 2016-09-30 | $0.22 |
| 2016-06-30 | $0.34 |
| 2016-03-31 | $0.49 |
| 2015-12-31 | $-0.03 |
| 2015-09-30 | $0.35 |
| 2015-06-30 | $0.43 |
| 2015-03-31 | $0.38 |
| 2014-12-31 | $0.20 |
| 2014-09-30 | $0.42 |
| 2014-06-30 | $0.46 |
| 2014-03-31 | $0.36 |
| 2013-12-31 | $0.46 |
| 2013-09-30 | $0.39 |
| 2013-06-30 | $2.00 |
| 2013-03-31 | $0.38 |
| 2012-12-31 | $0.85 |
| 2012-09-30 | $0.43 |
| 2012-06-30 | $0.44 |
| 2012-03-31 | $0.24 |
| 2011-12-31 | $0.19 |
| 2011-09-30 | $0.48 |
| 2011-06-30 | $0.33 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |